...
首页> 外文期刊>Frontiers in Pharmacology >Effects of Intensive Control of Glycemia on Clinical Kidney Outcomes in Type 2 Diabetes Patients Compared with Standard Control: A Meta-Analysis
【24h】

Effects of Intensive Control of Glycemia on Clinical Kidney Outcomes in Type 2 Diabetes Patients Compared with Standard Control: A Meta-Analysis

机译:严格控制血糖对2型糖尿病患者临床肾脏结局的影响与标准对照组相比的荟萃分析

获取原文

摘要

Background: Association between poor control of glycemia and the onset of microvascular complications in type 2 diabetes mellitus (T2DM) patients is a hard issue. However, it seems that the impact of pharmacological treatment is important only in early stages of diabetic nephropathy. We sought to examine whether intensive glycemic control is associated with improvement of clinical Chronic Kidney Disease (CKD) outcomes compared to standard glycemic control. Methods: Meta-analysis of published and unpublished randomized controlled trials (RCT) and post-hoc analysis of RCTs comparing anti-diabetic drugs and/or insulin (intensive control) vs. dietary measures (standard control) for relevant outcomes related to progression of CKD clinically manifest was undertaken. Summary estimates obtained by random effects model and funnel plots for assessing reporting bias are presented. Results: Our analysis was based on four RCTs representing 27,391 adult T2DM patients with CKD from around the world. The pooled OR for the outcomes of doubling of serum creatinine and need of dialysis were, respectively, of 0.98 with 95% confidence interval (95% CI) 0.81–1.19, and 0.84 with 95% CI 0.69–1.02. The pooled OR for the outcome of death from kidney failure was 0.62 with 95% CI 0.39–0.98. Clinical differences between studies were not translated in statistical heterogeneity. Reporting bias may be present. Conclusions: Intensive glycemic control has an effect on death from kidney failure compared to standard glycemic control. Better comprehension of glycemic control effects on both T2DM patients with and without CKD is important for individualization of these two treatment modalities.
机译:背景:血糖控制不佳与2型糖尿病(T2DM)患者的微血管并发症发作之间的关联是一个难题。然而,似乎仅在糖尿病性肾病的早期阶段,药物治疗的影响才是重要的。我们试图检查与标准的血糖控制相比,强化的血糖控制是否与临床慢性肾脏病(CKD)结局的改善相关。方法:对已发表和未发表的随机对照试验(RCT)进行荟萃分析,并对RCT进行事后分析,比较抗糖尿病药和/或胰岛素(强化对照)与饮食措施(标准对照)之间与糖尿病进展相关的结局进行了CKD临床表现。介绍了通过随机效应模型和漏斗图获得的摘要估计值,以评估报告偏差。结果:我们的分析基于代表世界各地27,391名CKD成人T2DM患者的四个RCT。血清肌酐加倍和需要透析的合并OR分别为0.98和95%置信区间(95%CI)0.81–1.19,以及0.84和95%CI 0.69–1.02。合并肾功能衰竭死亡的OR为0.62,95%CI为0.39-0.98。研究之间的临床差异未转化为统计异质性。报告偏差可能存在。结论:与标准血糖控制相比,强化血糖控制对肾衰竭死亡具有影响。对于有和没有CKD的T2DM患者,更好地了解血糖控制效果对于个体化这两种治疗方式很重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号